Organon and Samsung Bioepis Expand Agreement to Commercialize PYZCHIVA® (ustekinumab), a Biosimilar Referencing STELARA® (ustekinumab) in Canada

Organon and Samsung Bioepis Expand Agreement to Commercialize PYZCHIVA® (ustekinumab), a Biosimilar ReferencingSTELARA® (ustekinumab) in Canada

The amended agreement deepens Organon and Samsung Bioepis’s collaboration to six biosimilars in Canada across multiple therapeutic areas, including immunology, oncology and dermatology.

To be launched in Canada in 2026

Samsung Bioepis andOrganon, a global healthcare company with a deep expertise in biosimilars, announced the expansion of their development and commercialization agreement, whereby Organon will obtain commercialization rights in Canada to PYZCHIVA®, Samsung Bioepis’s biosimilar referencing STELARA® (ustekinumab).

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260618749080/en/